Stem Cells Market Size Worth $17.78 Bn by 2027, with Leading Industry Players – Celgene Corporation, ReNeuron Group plc, Virgin Health Bank, Biovault Family and More

April 07 20:49 2021
Stem Cells Market Size Worth $17.78 Bn by 2027, with Leading Industry Players - Celgene Corporation, ReNeuron Group plc, Virgin Health Bank, Biovault Family and More

Stem Cells Market
The growing prevalence of target disease prevalence and increasing adoption of stem cell therapies for chronic disease treatment is driving the market growth.

The global Stem Cells Market size is estimated to reach USD 17.78 billion from USD 9.35 billion in 2019, delivering a CAGR of 8.4% through 2027. The market growth is driven by the huge success of regenerative medicine and an exponential rise in stem cell-based research activities.

Stem cell offers several benefits over many surgical options as it stimulates the natural healing response by utilizing the cells sourced from the same patient instead of artificial implants or a prosthetic replacement. It also eliminates the need for surgery as well as any post-treatment complications or risks associated with surgery.

Positive government initiatives supporting stem cell banking is several countries across the globe will boost the market growth. In addition, rise in the number of stem cell banks, especially across the developing nations, will supplement stem cells market share over the coming years.

Rising outbreaks of infections have led to the development of vaccines using different non-tumorigenic cell lines and human diploids. The rise in ongoing R&D for the development of vaccines against various chronic diseases will foster stem cells market revenue share through 2027.

Request free sample of this research report at :

Key findings in the report:

  • The growing prevalence of cancer and an exponential demand for effective management and treatment of the disease is driving stem cells market growth.
  • According to the WHO, there were nearly 18.1 million new cases and 9.6 million deaths in 2018. Cancer Research UK estimates that there will be approximately 27.5 million new cases each year across the globe by 2040. 
  • On the basis of product type, the induced pluripotent stem cells segment is estimated to register the maximum growth rate through 2027 due to its potential to significantly advance drug development & clinical research.
  • Based on therapy outlook, the autologous stem cell therapy segment is forecast to exhibit a growth rate of 8.6% over the analysis period. The robust growth can be attributed to the low risk of complications associated with this treatment. Moreover, the improved survival rate of patients, no need for identification of an HLA-matched donor, affordability, as well as no risk of graft-versus-host diseases are some of the factors leading to the popularity of the autologous stem cell therapy.
  • Based on application, the regenerative medicine segment is poised to showcase a CAGR of 8.5% through 2027 on account of the development of cutting-edge orthopedic treatments involving stem cell therapy, which enable boosting recovery time, pain relief, increases mobility, and eliminates the need for invasive surgery such as joint replacements, or any kind of medications.
  • North America accounted for the majority of the stem cells market share in 2019 and is set to contribute significantly to the market revenue share through 2027 due to high R&D investments in cytological research in the region. Additionally, increased preference for stem cell therapies, advanced healthcare infrastructure, and strong reimbursement framework are some other factors bolstering regional industry growth.
  • Europe is anticipated to witness a growth rate of 8.5% over the projected timeframe.
  • The Asia Pacific region is expected to hold 22% of the global stem cells market share by 2027 due to several product pipelines in cell-based therapies and a large patient population.
  • Key participants contributing to the global stem cells market share include Celgene Corporation, ReNeuron Group plc, Virgin Health Bank, Biovault Family, Mesoblast Ltd., Caladrius, Opexa Therapeutics, Inc., Precious Cells International Ltd., Pluristem, and Neuralstem, Inc., among others.
  • In 2018, Kineta Immuno-Oncology, LLC, a subsidiary of Kineta Inc, a clinical-stage biotechnology company, entered into a research collaboration & license agreement with Pfizer Inc. to develop RIG-I agonist immunotherapies for the treatment of cancer.

Stem Cells Market By Product, By Technology, By Therapies, And By Application, Forecasts To 2027, To identify the key trends in the industry, click on the link below:

For the purpose of this report, Reports and Data has segmented into the global Stem Cells market on the basis of product, technology, therapy, application, and region:

Product Outlook (Revenue, USD Billion; 2017-2027)

  • Adult stem cells
    • Neuronal stem cells
    • Mesenchymal stem cells
    • Hematopoietic stem cells
    • Umbilical cord stem cells
    • Adipose‐derived stem cells
    • Dental stem cells
    • Dedifferentiated fat (DFAT) cells
    • Other adult-derived stem cells
  • Human embryonic stem cells
  • IPS cells
  • Very small embryonic like stem cells

Technology Outlook (Revenue, USD Billion; 2017-2027)

  • Cell acquisition
    • Umbilical cord blood
    • Bone marrow harvest
    • Apheresis
  • Cell Production
    • Therapeutic cloning
    • Cell culture
    • In-vitro Fertilization
    • Isolation
  • Cryopreservation
  • Expansion and sub-culture

Therapy Outlook (Revenue, USD Billion; 2017-2027)

  • Allogenic Stem Cell Therapy
  • Autologous Stem Cell Therapy

Application Outlook (Revenue, USD Billion; 2017-2027)

  • Regenerative medicine
    • Orthopedics
    • Neurology
    • Hematology stem cells
    • Soft tissue injuries
    • Cardiovascular and myocardial infarction-based
    • Diabetes
    • Oncology
    • Liver disorder
    • Others
  • Drug discovery & development

Order Now:

Regional Outlook (Revenue in USD Billion; 2017–2027)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Egypt
    • Rest of MEA

Table Of Content

Chapter 1. Market Synopsis

   1.1. Market Definition

    1.2. Research Scope & Premise

    1.3. Methodology

    1.4. Market Estimation Technique

Chapter 2. Executive Summary

    2.1. Summary Snapshot, 2019-2027

Chapter 3. Indicative Metrics

Chapter 4. Stem Cells Market Segmentation & Impact Analysis

    4.1. Stem Cells Market Material Segmentation Analysis

    4.2. Industrial Outlook


Chapter 10. Competitive Landscape

    10.1. Market Revenue Share By Manufacturers

    10.2. Manufacturing Cost Breakdown Analysis

    10.3. Mergers & Acquisitions

    10.4. Market positioning

    10.5. Strategy Benchmarking

    10.6. Vendor Landscape

Chapter 11. Company Profiles

    11.1. Celgene Corporation

            11.1.1. Company Overview

            11.1.2. Financial Performance

            11.1.3. Technology Insights

            11.1.4. Strategic Initiatives

    11.2. Virgin Health Bank

           11.2.1. Company Overview

           11.2.2. Financial Performance

           11.2.3. Technology Insights

           11.2.4. Strategic Initiatives

    11.3. ReNeuron Group plc

            11.3.1. Company Overview

            11.3.2. Financial Performance

            11.3.3. Technology Insights

            11.3.4. Strategic Initiatives

    11.4. Biovault Family

           11.4.1. Company Overview

           11.4.2. Financial Performance

           11.4.3. Technology Insights

           11.4.4. Strategic Initiatives

    11.5. Mesoblast Ltd

            11.5.1. Company Overview

            11.5.2. Financial Performance

            11.5.3. Technology Insights

            11.5.4. Strategic Initiatives

Continue …

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Media Contact
Company Name: Reports and Data
Contact Person: John Watson
Email: Send Email
Phone: +1-212-710-1370
Address:40 Wall St. 28th floor
City: New York City
State: NY 10005
Country: United States